Navigation Links
Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
Date:9/26/2007

phine-induced constipation, while maintaining substantial central analgesic effect. In addition, orally-administered NKTR-118 had a favorable safety and pharmacokinetic profile in an animal model.

About NKTR-118

NKTR-118 is an oral drug that combines Nektar's advanced small molecule PEGylation technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. In preclinical studies, Nektar's PEGylation technology has been shown to prevent oral NKTR-118 from crossing the blood-brain barrier, an important potential advance for this and possibly many other small molecule therapies.

The antagonist NKTR-118 targets mu-opioid receptors within the enteric nervous system, which mediate OBD, a symptom complex resulting from opioid use that encompasses constipation, bloating, abdominal cramping, and gastroesophageal reflux. Constipation is the hallmark of this syndrome, and is generally its most prominent component. NKTR-118 is currently in a second Phase 1 trial to evaluate the safety and tolerability of repeated dose administration.

According to IMS Health, more than 200 million prescriptions were written for opioids in 2006 in the United States, alone. Many studies indicate that a high percentage of patients receiving opioids are likely to experience significant constipation and other symptoms of OBD. Currently, there are no specific drugs approved that are indicated to treat OBD or OIC. Stool softeners or laxatives may be ineffective for many patients with OIC and they are often associated with side effects like diarrhea and cramping.

Data Presentations for NKTR-118

The NKTR-118 poster presentations from this week's American Academy of Pain Management's Annual Clinical Meeting in Las Vegas, Nevada from September 27-30, 2007 can be found on Nektar's website at http://www.nektar.com/wt/page/nktr118_media:

Poster #27: "Clinical Investigation
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, Inc. ... tissue protection, repair and regeneration, today announced that ... scheduled to present a corporate overview at two upcoming ... at the SeeThruEquity 4 th Annual Microcap Conference ... York City at 11:00 am EDT.  A ...
(Date:5/22/2015)... and KING OF PRUSSIA, Pa. , May ... has awarded CSL Behring its 2015 Corporate Leadership ... to advancing science and improving the care of the bleeding ... , CEO and Managing Director, CSL Limited, during the NHF ... on May 21. "The National Hemophilia Foundation ...
(Date:5/22/2015)... WASHINGTON , May 22, 2015  The ... certain diagnosed victims of mesothelioma get the best ... making certain individuals with this rare cancer caused ... the most up-to-date information related to treatment options ... information please call the Mesothelioma Victims Center anytime ...
Breaking Medicine Technology:RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5
... on the Menopause show significant, improvement in vaginal ... ... ARBOR, Mich., May 21 QuatRx Pharmaceuticals today,announced further ... Ophena(TM),(ospemifene tablets) to treat postmenopausal women with symptoms of,vulvovaginal ...
... Mass., May 21 Pressure,BioSciences, Inc. (Nasdaq: ... New York University (NYU) School of Medicine, the ... Health made presentations,highlighting the advantages of the Company,s ... meetings earlier this week.,There were three oral presentations ...
Cached Medicine Technology:QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy 2QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy 3Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City 2Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City 3Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City 4
(Date:5/22/2015)... Philadelphia, PA (PRWEB) May 22, 2015 According ... as a hub for drug related death, totaling almost 2,500 ... number, as reported by state officials, totals 2,489 deaths stemming ... numbers work out, Pennsylvania loses seven people every day to ... Philadelphia has been singled out as one of the most ...
(Date:5/22/2015)... 2015 Gateway Building Concepts is experienced ... services the company specialize in include decks, additions, kitchen ... houses and much more. , The redesigned logo ... of the company. It includes two geometrical lines that ... thought out to be used with many things associated ...
(Date:5/22/2015)... 2015 sweetFrog Enterprises, LLC. is pleased to ... Jacksonville is now the 16th sweetFrog store located in the ... as #22 on the Inc. 500 list of fastest growing ... worked in East Texas for 20 years and love the ... the Jacksonville, and nearby Palestine, sweetFrog locations. “We are really ...
(Date:5/22/2015)... Wimbledon Health Partners, the leading on-site diagnostic ... NCV testing , is proud to announce the ... National athlete, to the Wimbledon Athletics division. , ... of testing and information it provides to be extremely ... this way they can focus on the task at ...
(Date:5/22/2015)... New York, NY (PRWEB) May 22, 2015 ... Bay Lightning vs. New York Rangers NHL Eastern Conference Finals ... finals is together unless specified otherwise in the ticket listing. ... New York Rangers are at the top of the Eastern ... League has had its share of ups and downs over ...
Breaking Medicine News(10 mins):Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 3
... firms, who produce cheap imitations of Viagra have launched an ... patent rights // in the world's most populous nation which ... last-ditch effort to protect their investment in Viagra-style drugs, the ... Court. ,They are calling for a reversal of ...
... According to a report put forth ... of nursing education of Witwatersrand ... prone to suffer from anemia and ... pregnancy and eventually deliver babies ...
... REM Sleep Behavior Disorder (RBD). The study conducted by ... of this disorder at a younger age. ... out their dreams, which are often unpleasant and violent, ... and study investigator. This acting out results from a ...
... U.S. researchers on the medical histories of patients not ... or suffered weak eyesight, revealed that they had undergone ... deficiency, leading to poor eyesight or even blindness. This ... British Journal of Ophthalmology. ,The study analyzed ...
... to reduce the symptoms related with fibromyalgia such as ... a condition with unknown cause, characterized by episodes of ... So treatment generally involves a combination of painkillers, antidepressants ... participated in the study (for 2 to 3 weeks) ...
... some sun protection creams have the potential to cause nerve ... may not necessarily imply that these microscopic grains, which are ... cosmetics, are harmful in the human body, Nature magazine said ... that a growing body of evidence suggests their safety cannot ...
Cached Medicine News:
These handy dispensers save space and organize gloves in labs and next to hand washers. Clear acrylic. Many other sizes and custom configurations available....
Single side double clamp knife holder for the Vibratome 8000...
... The Professional Gold Package is ... laboratory. The package includes the ... automated system, standard accessory kit, ... specimen mounts 1/2" head, rotating ...
... 1000 Sectioning System provides a versatile means ... plant tissues. The 1000 employs a ... freezing or embedding. The creation of ... of enzyme activities, and other deleterious effects ...
Medicine Products: